-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Globus Medical, Inc. (NYSE:GMED), is not the largest company out there, but it led the NYSE gainers with a relatively large price hike in the past couple of weeks. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, what if the stock is still a bargain? Let's examine Globus Medical's valuation and outlook in more detail to determine if there's still a bargain opportunity.
View our latest analysis for Globus Medical
Is Globus Medical Still Cheap?
Globus Medical appears to be expensive according to my price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average. I've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 40.96x is currently well-above the industry average of 33.36x, meaning that it is trading at a more expensive price relative to its peers. If you like the stock, you may want to keep an eye out for a potential price decline in the future. Since Globus Medical's share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.
What kind of growth will Globus Medical generate?
NYSE:GMED Earnings and Revenue Growth August 10th 2022Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. Globus Medical's earnings over the next few years are expected to increase by 67%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.
What This Means For You
Are you a shareholder? GMED's optimistic future growth appears to have been factored into the current share price, with shares trading above industry price multiples. At this current price, shareholders may be asking a different question – should I sell? If you believe GMED should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.
Are you a potential investor? If you've been keeping tabs on GMED for some time, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the optimistic prospect is encouraging for GMED, which means it's worth diving deeper into other factors in order to take advantage of the next price drop.
It can be quite valuable to consider what analysts expect for Globus Medical from their most recent forecasts. Luckily, you can check out what analysts are forecasting by clicking here.
If you are no longer interested in Globus Medical, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Globus Medical,Inc.(纽约证券交易所代码:GMED)并不是最大的公司,但它在过去几周内以相对较大的涨幅领涨了纽约证券交易所的涨幅。作为一只分析师覆盖率很高的中型股,你可以假设该公司最近前景的任何变化都已经计入了股价。然而,如果这只股票仍然是便宜货呢?让我们更详细地研究Globus Medical的估值和前景,以确定是否仍有讨价还价的机会。
查看我们对Globus Medical的最新分析
Globus Medical还便宜吗?
根据我的市盈率模型,Globus Medical似乎很贵,该模型将该公司的市盈率与行业平均水平进行了比较。我之所以在这种情况下使用市盈率,是因为没有足够的可见性来预测其现金流。该股目前的市盈率为40.96倍,远高于33.36倍的行业平均水平,这意味着它的交易价格比同行更高。如果你喜欢这只股票,你可能想要密切关注未来可能的价格下跌。由于Globus Medical的股价波动很大,这可能意味着它未来可能会下跌(或进一步上涨),给我们另一个投资机会。这是基于其较高的贝塔系数,这是衡量该股相对于市场其他股票波动程度的一个很好的指标。
Globus Medical将带来怎样的增长?
纽约证券交易所:GMED收益和收入增长2022年8月10日当你考虑购买一只股票时,未来前景是一个重要的方面,特别是如果你是一个寻求投资组合增长的投资者。以低廉的价格收购一家前景稳健的伟大公司永远是一笔不错的投资,所以让我们也来看看该公司的未来预期。Globus Medical未来几年的收益预计将增长67%,这表明未来非常乐观。这应该会带来更强劲的现金流,从而带来更高的股价。
这对你意味着什么
你是股东吗?GMED乐观的未来增长似乎已被计入当前股价,股价高于行业市盈率。在目前的价格下,股东们可能会问一个不同的问题--我应该卖出吗?如果你认为GMED的交易价格应该低于当前价格,那么当其价格跌至行业水平时,逢高抛售并再次买入,市盈率可能会有利可图。但在你做出这个决定之前,先看看它的基本面是否发生了变化。
你是潜在的投资者吗?如果你关注GMED已经有一段时间了,现在可能不是买入该股的最佳时机。这一价格已经超过了业内同行,这意味着错误定价很可能不会带来更多的好处。然而,乐观的前景对GMED来说是令人鼓舞的,这意味着为了利用下一次价格下跌,值得更深入地研究其他因素。
考虑分析师从他们最新的预测中对Globus Medical的预期可能是相当有价值的。幸运的是,您可以通过单击此处查看分析师的预测。
如果您对Globus Medical不再感兴趣,您可以使用我们的免费平台查看我们的其他50多只具有高增长潜力的股票。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧